AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10402150 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone maintenance treatment (MMT)
Number of subjects: 0
Study 10402150 — intervention group
Group type: COMPARATOR
Intervention: No benzodiazepine abuse at the beginning of MMT
Number of subjects: 0
Study 10402150 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepine types abused
Number of subjects: 0
Study 10402150 — intervention group
Group type: EXPERIMENTAL
Intervention: Method of BZD use
Number of subjects: 0
Study 10402150 — intervention group
Group type: EXPERIMENTAL
Intervention: Reason for BZD use
Number of subjects: 0
Study 7595712 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (20 mg/m2) plus Etoposide (100 mg/m2) (VP)
Number of subjects: 171
Study 7595712 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (20 mg/m2), Ifosfamide (1.2 g/m2), and Etoposide (75 mg/m2) (VIP)
Number of subjects: 171
Study 2135137 — intervention group
Group type: EXPERIMENTAL
Intervention: GaAlAs laser diode treatment (active group)
Number of subjects: 67
Study 2135137 — intervention group
Group type: COMPARATOR
Intervention: Dummy group (control)
Number of subjects: 67
Study 380254 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 24
Study 380254 — intervention group
Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 24
Study 31585778 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel/prednisone (control arm of 3 trials)
Number of subjects: 1600
Study 31488083 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-oncological group intervention for partners of patients with haemato-oncological diseases
Number of subjects: 0
Study 31488083 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 27956455 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual oral azithromycin treatment of the entire community
Number of subjects: 48
Study 27956455 — intervention group
Group type: COMPARATOR
Intervention: Biannual treatment of children aged 0-12 years only
Number of subjects: 48
Study 25884271 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive airway pressure (PAP) at 1,320 m
Number of subjects: 10
Study 25884271 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive airway pressure (PAP) at 2,750 m
Number of subjects: 10
Study 25884271 — intervention group
Group type: COMPARATOR
Intervention: No positive airway pressure at 2,750 m
Number of subjects: 10
Study 23667214 — intervention group
Group type: EXPERIMENTAL
Intervention: DBS surgery
Number of subjects: 255
Study 23667214 — intervention group
Group type: COMPARATOR
Intervention: Best Medical Therapy (BMT)
Number of subjects: 255
Study 23667214 — intervention group
Group type: EXPERIMENTAL
Intervention: STN DBS
Number of subjects: 255
Study 23667214 — intervention group
Group type: COMPARATOR
Intervention: GPi DBS
Number of subjects: 255
Study 21829748 — intervention group
Group type: EXPERIMENTAL
Intervention: rDEN1Δ30 vaccine (2 doses, subcutaneous)
Number of subjects: 60
Study 21829748 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 doses)
Number of subjects: 60
Study 19780066 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of myocardial infarction (MI) in at least one first-degree relative
Number of subjects: 2642
Study 19780066 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of MI in two or more first-degree relatives
Number of subjects: 2642
Study 19780066 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated systolic blood pressure (SBP)
Number of subjects: 2642
Study 19780066 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated diastolic blood pressure (DBP)
Number of subjects: 2642
Study 19780066 — intervention group
Group type: EXPERIMENTAL
Intervention: Two or more episodes per week of physical activity
Number of subjects: 2642
Study 17191270 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia training with peer support group
Number of subjects: 90
Study 17191270 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia training only
Number of subjects: 90
Study 17191270 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 90
Study 15494348 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus diclofenac (n = 48)
Number of subjects: 97
Study 15494348 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture plus diclofenac (n = 49)
Number of subjects: 97
Study 11251955 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) alone
Number of subjects: 397
Study 11251955 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) with levamisole
Number of subjects: 397
Study 11251955 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) with hepatic irradiation
Number of subjects: 397
Study 11251955 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil (5-FU) alone (Group A)
Number of subjects: 397
Study 11251955 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil (5-FU) with levamisole (Group A)
Number of subjects: 397
Study 9572698 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine/prilocaine cream 5% (n = 64)
Number of subjects: 128
Study 9572698 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 64)
Number of subjects: 128
Study 8073064 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice (200 ml at 0, 2, 4, 8 and 12 h)
Number of subjects: 10
Study 8073064 — intervention group
Group type: COMPARATOR
Intervention: Control (no grapefruit juice)
Number of subjects: 10
Study 3392421 — intervention group
Group type: EXPERIMENTAL
Intervention: Killed whole cell (WC) oral cholera vaccine
Number of subjects: 62285
Study 3392421 — intervention group
Group type: EXPERIMENTAL
Intervention: B subunit‐killed whole cell (BS‐WC) oral cholera vaccine
Number of subjects: 62285
Study 3392421 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 62285
Study 31717931 — intervention group
Group type: EXPERIMENTAL
Intervention: Written physical activity policy implemented for 8 weeks
Number of subjects: 8
Study 31717931 — intervention group
Group type: EXPERIMENTAL
Intervention: Surveys and interviews with childcare staff
Number of subjects: 8
Study 31717931 — intervention group
Group type: EXPERIMENTAL
Intervention: Environment and Policy Assessment and Observation Self‐Report tool
Number of subjects: 8
Study 31717931 — intervention group
Group type: EXPERIMENTAL
Intervention: Study-specific questionnaire for childcare providers
Number of subjects: 8
Study 31717931 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear mixed effects models
Number of subjects: 8
Study 31717931 — intervention group
Group type: EXPERIMENTAL
Intervention: Descriptive statistics and thematic analysis
Number of subjects: 8
Study 28463882 — intervention group
Group type: EXPERIMENTAL
Intervention: ART (emtricitabine/tenofovir disoproxil fumarate + lopinavir/ritonavir) + raltegravir + maraviroc
Number of subjects: 22
Study 28463882 — intervention group
Group type: COMPARATOR
Intervention: ART (emtricitabine/tenofovir disoproxil fumarate + lopinavir/ritonavir) + placebo
Number of subjects: 22
Study 28463882 — intervention group
Group type: EXPERIMENTAL
Intervention: ART intensification with raltegravir and maraviroc
Number of subjects: 22
Study 26133944 — intervention group
Group type: EXPERIMENTAL
Intervention: HA + CS injection
Number of subjects: 57
Study 26133944 — intervention group
Group type: COMPARATOR
Intervention: triamcinolone injection
Number of subjects: 57
Study 24054816 — intervention group
Group type: EXPERIMENTAL
Intervention: London Stroke Carers Training Course (LSCTC)
Number of subjects: 928
Study 24054816 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 928
Study 20861135 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF 5 μg/kg b.i.d. subcutaneously for 5 days
Number of subjects: 60
Study 20861135 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 18806100 — intervention group
Group type: EXPERIMENTAL
Intervention: Shea butter blend (SA)
Number of subjects: 17
Study 18806100 — intervention group
Group type: COMPARATOR
Intervention: High oleic sunflower oil (HO)
Number of subjects: 17
Study 18806100 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of meals (SA vs HO)
Number of subjects: 17
Study 18806100 — intervention group
Group type: EXPERIMENTAL
Intervention: Shea butter blend (SA) and High oleic sunflower oil (HO)
Number of subjects: 17
Study 15933223 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap vaccine (0.5-mL intramuscular dose)
Number of subjects: 4480
Study 15933223 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap vaccine
Number of subjects: 4480
Study 15933223 — intervention group
Group type: COMPARATOR
Intervention: Td vaccine (Td)
Number of subjects: 4480
Study 12534409 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen 40 mg p.o.
Number of subjects: 18
Study 12534409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 12764802 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS)
Number of subjects: 42
Study 8538352 — intervention group
Group type: EXPERIMENTAL
Intervention: Holmium:YAG laser endoscopic sinus surgery
Number of subjects: 32
Study 8538352 — intervention group
Group type: COMPARATOR
Intervention: Conventional endoscopic instrumentation
Number of subjects: 32
Study 1678220 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg terfenadine
Number of subjects: 12
Study 1678220 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg terfenadine
Number of subjects: 12
Study 1678220 — intervention group
Group type: EXPERIMENTAL
Intervention: 240 mg terfenadine
Number of subjects: 12
Study 1678220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6781588 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobilisation with or without physiotherapy
Number of subjects: 0
Study 6781588 — intervention group
Group type: COMPARATOR
Intervention: Immobilisation in plaster‐of‐Paris
Number of subjects: 0
Study 6781588 — intervention group
Group type: COMPARATOR
Intervention: No treatment with minimal bandage
Number of subjects: 0
Study 6781588 — intervention group
Group type: COMPARATOR
Intervention: Tubigrip support
Number of subjects: 0
Study 6781588 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 0
Study 31034978 — intervention group
Group type: EXPERIMENTAL
Intervention: EMIG laparoscopic and hysteroscopic simulation systems
Number of subjects: 27
Study 30616811 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week cardiac rehabilitation program
Number of subjects: 130
Study 30616811 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 130
Study 28578210 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine refusal vignette
Number of subjects: 1469
Study 28578210 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine delay vignette
Number of subjects: 1469
Study 28578210 — intervention group
Group type: EXPERIMENTAL
Intervention: Social barriers vignette
Number of subjects: 1469
Study 28578210 — intervention group
Group type: COMPARATOR
Intervention: Up-to-date vaccines vignette
Number of subjects: 1469
Study 26041849 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted surgery
Number of subjects: 57
Study 26041849 — intervention group
Group type: COMPARATOR
Intervention: Conventional total knee arthroplasty
Number of subjects: 57
Study 24135027 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based health coaching
Number of subjects: 12000
Study 24135027 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 12000
Study 21236408 — intervention group
Group type: EXPERIMENTAL
Intervention: Stromal hydration
Number of subjects: 30
Study 21236408 — intervention group
Group type: COMPARATOR
Intervention: No stromal hydration
Number of subjects: 30
Study 20020793 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial infiltration of a cartridge of 4% articaine with 1:100,000 epinephrine plus a repeated infiltration of the same anesthetic and dose given 25 minutes following the initial infiltration
Number of subjects: 86
Study 20020793 — intervention group
Group type: COMPARATOR
Intervention: Initial infiltration of a cartridge of 4% articaine with 1:100,000 epinephrine plus a mock repeated infiltration given 25 minutes following the initial infiltration
Number of subjects: 86
Study 16703187 — intervention group
Group type: EXPERIMENTAL
Intervention: IV tirofiban infusion before the lesion was crossed with the guidewire
Number of subjects: 111
Study 16703187 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy including preprocedural aspirin, ticlopidine, and IV heparin
Number of subjects: 111
Study 14990647 — intervention group
Group type: EXPERIMENTAL
Intervention: CCI-779 (25, 75, or 250 mg weekly as a 30-minute intravenous infusion)
Number of subjects: 111
Study 11350112 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training for 12 weeks
Number of subjects: 12
Study 9184576 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous immune globulin infusions (2 g/kg)
Number of subjects: 10
Study 8214465 — intervention group
Group type: EXPERIMENTAL
Intervention: Powdered ginger root
Number of subjects: 120
Study 8214465 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 120
Study 8214465 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 8214465 — intervention group
Group type: COMPARATOR
Intervention: Powdered ginger root, Metoclopramide, Placebo
Number of subjects: 120
Study 3305592 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose reserpine
Number of subjects: 9
Study 3305592 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 31472087 — intervention group
Group type: EXPERIMENTAL
Intervention: Alveolar ridge preservation with adjunctive use of enamel matrix derivative (EMD)
Number of subjects: 30
Study 31472087 — intervention group
Group type: COMPARATOR
Intervention: Alveolar ridge preservation without enamel matrix derivative (EMD)
Number of subjects: 30
Study 29781043 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 day course of antibiotics (Group 1)
Number of subjects: 70
Study 29781043 — intervention group
Group type: COMPARATOR
Intervention: 7 day course of antibiotics (Group 2)
Number of subjects: 70
Study 27438395 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted strategy including baseline measurements, education, reminders, and optional improvement interventions
Number of subjects: 1964
Study 27438395 — intervention group
Group type: COMPARATOR
Intervention: Competitive feedback strategy with baseline measurements and non-anonymous results from other departments
Number of subjects: 1964
Study 24268723 — intervention group
Group type: EXPERIMENTAL
Intervention: Active cTBS treatment
Number of subjects: 12
Study 24268723 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 12
Study 23036896 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 5 mg twice daily (n=9120)
Number of subjects: 18201
Study 23036896 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (target INR 2.0-3.0; n=9081)
Number of subjects: 18201
Study 23036896 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 18201
Study 20519097 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical glucocorticoid (GC) spray treatment for one month
Number of subjects: 80
Study 17586780 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20-40 mg/day)
Number of subjects: 0
Study 17586780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15141721 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic doxycycline (SD) alone
Number of subjects: 45
Study 15141721 — intervention group
Group type: COMPARATOR
Intervention: Systemic doxycycline (SD) + scaling-root planing (SD+SRP)
Number of subjects: 45
Study 15141721 — intervention group
Group type: EXPERIMENTAL
Intervention: Local doxycycline (LD) alone
Number of subjects: 45
Study 15141721 — intervention group
Group type: COMPARATOR
Intervention: Local doxycycline (LD) + scaling-root planing (LD+SRP)
Number of subjects: 45
Study 15141721 — intervention group
Group type: COMPARATOR
Intervention: Scaling-root planing (SRP) alone
Number of subjects: 45
Study 11680657 — intervention group
Group type: COMPARATOR
Intervention: Cadaveric graft
Number of subjects: 79
Study 11680657 — intervention group
Group type: COMPARATOR
Intervention: Living-related donor graft
Number of subjects: 79
Study 11680657 — intervention group
Group type: EXPERIMENTAL
Intervention: IgAN patients
Number of subjects: 79
Study 9622910 — intervention group
Group type: EXPERIMENTAL
Intervention: Rule-based and exemplar-based categorization
Number of subjects: 0
Study 9622910 — intervention group
Group type: EXPERIMENTAL
Intervention: Instance frequency
Number of subjects: 0
Study 7937278 — intervention group
Group type: EXPERIMENTAL
Intervention: Aconiazide tablets 650 mg (containing isoniazid 300 mg)
Number of subjects: 12
Study 7937278 — intervention group
Group type: COMPARATOR
Intervention: Isoniazid tablets 300 mg
Number of subjects: 12
Study 3286128 — intervention group
Group type: EXPERIMENTAL
Intervention: tizanidine hydrochloride
Number of subjects: 100
Study 3286128 — intervention group
Group type: COMPARATOR
Intervention: baclofen
Number of subjects: 100
Study 29658989 — intervention group
Group type: EXPERIMENTAL
Intervention: Group self-management education course
Number of subjects: 404
Study 29658989 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 404
Study 27609509 — intervention group
Group type: EXPERIMENTAL
Intervention: Soya milk
Number of subjects: 12
Study 27609509 — intervention group
Group type: EXPERIMENTAL
Intervention: Cows' milk
Number of subjects: 12
Study 27609509 — intervention group
Group type: COMPARATOR
Intervention: Control (water)
Number of subjects: 12
Study 27609509 — intervention group
Group type: COMPARATOR
Intervention: Soya milk and Cows' milk
Number of subjects: 12
Study 25218689 — intervention group
Group type: EXPERIMENTAL
Intervention: EMPOWER-PAR intervention (multifaceted chronic disease management strategies)
Number of subjects: 10
Study 25218689 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 10
Study 22451015 — intervention group
Group type: EXPERIMENTAL
Intervention: ConcordantRx instructions
Number of subjects: 202
Study 22451015 — intervention group
Group type: COMPARATOR
Intervention: Standard instructions
Number of subjects: 202
Study 20504840 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoidectomy
Number of subjects: 217
Study 20504840 — intervention group
Group type: COMPARATOR
Intervention: Control (no adenoidectomy)
Number of subjects: 217
Study 18210334 — intervention group
Group type: EXPERIMENTAL
Intervention: NuvaRing
Number of subjects: 25
Study 18210334 — intervention group
Group type: COMPARATOR
Intervention: Control (no contraception)
Number of subjects: 25
Study 18210334 — intervention group
Group type: COMPARATOR
Intervention: NuvaRing (healthy women)
Number of subjects: 25
Study 16175328 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 percent diltiazem ointment
Number of subjects: 18
Study 16175328 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 18
Study 15492949 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 399
Study 15492949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 399
Study 11337622 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonoperative treatment with early mobilization using a hyperextension brace (n = 47)
Number of subjects: 80
Study 11337622 — intervention group
Group type: COMPARATOR
Intervention: Short-segment posterior fixation using VSP or TSRH instrumentation (n = 33)
Number of subjects: 80
Study 9444298 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan alone
Number of subjects: 770
Study 9444298 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan plus enalapril
Number of subjects: 770
Study 9444298 — intervention group
Group type: COMPARATOR
Intervention: Enalapril alone
Number of subjects: 770
Study 9444298 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 770
Study 9444298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 770
Study 9444298 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan, enalapril, metoprolol
Number of subjects: 770
Study 8197779 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast conservation consisting of wide breast resection (quadrantectomy) plus radiotherapy
Number of subjects: 0
Study 8197779 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrantectomy alone (without radiotherapy) in women older than 55 years
Number of subjects: 0
Study 8197779 — intervention group
Group type: COMPARATOR
Intervention: Reducing surgery from quadrantectomy to lumpectomy
Number of subjects: 0
Study 8197779 — intervention group
Group type: COMPARATOR
Intervention: Withdrawing radiotherapy
Number of subjects: 0
Study 3225202 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral visual half-field stimulation
Number of subjects: 14
Study 3225202 — intervention group
Group type: COMPARATOR
Intervention: Ipsilateral visual half-field stimulation
Number of subjects: 14
Study 31376798 — intervention group
Group type: EXPERIMENTAL
Intervention: Bangla version of the Dimensions of Mastery Questionnaire (DMQ-18)
Number of subjects: 206
Study 28408145 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepilex Ag™
Number of subjects: 96
Study 28408145 — intervention group
Group type: EXPERIMENTAL
Intervention: Acticoat™ with Mepitel™
Number of subjects: 96
Study 28408145 — intervention group
Group type: COMPARATOR
Intervention: Acticoat™
Number of subjects: 96
Study 25187111 — intervention group
Group type: EXPERIMENTAL
Intervention: 4‐STEPS program (self‐regulation based physical activity program)
Number of subjects: 91
Study 25187111 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control condition)
Number of subjects: 91
Study 24190927 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 244
Study 24190927 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine CR
Number of subjects: 244
Study 20350955 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine 10 or 15 mg
Number of subjects: 57
Study 18513345 — intervention group
Group type: EXPERIMENTAL
Intervention: Moving during a 2-hour observation period in bed after coronary angiography
Number of subjects: 1000
Study 18513345 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen (lying still during observation period)
Number of subjects: 1000